Search
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigationalMisoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.
19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicit19-Nor-5-andorstenedione is a prohormone which has the potential to affect bodily levels of testosterone once metabolized in vivo. … It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.
4-Methoxyamphetamine
go.drugbank.com/drugs/DB01472ExperimentalIllicitCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesMetrizamide
go.drugbank.com/drugs/DB01578ExperimentalIt is also used as a resorbable, non-ionic contrast medium. … Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity.
Categories: Compounds used in a research, industrial, or household settingAZD3409
go.drugbank.com/drugs/DB04893ExperimentalAZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.
Stannsoporfin
go.drugbank.com/drugs/DB04912InvestigationalStannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing
Alfimeprase
go.drugbank.com/drugs/DB04919InvestigationalAlfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). … It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.